Ubs Group Ag Nuvation Bio Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Ubs Group Ag holds 399,583 shares of NUVB stock, worth $935,024. This represents 0.0% of its overall portfolio holdings.

Number of Shares

399,583

Previous 423,802 5.71%

Holding current value

$935,024

Previous $1.54 Million 24.38%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.58 - $3.69 $62,485 - $89,368	-24,219 Reduced 5.71%	399,583 $1.17 Million
Q1 2024 May 13, 2024	BUY	$1.46 - $3.97 $62,025 - $168,657	42,483 Added 11.14%	423,802 $1.54 Million
Q4 2023 Feb 09, 2024	BUY	$0.96 - $1.53 $274,284 - $437,140	285,713 Added 298.84%	381,319 $575,000
Q3 2023 Nov 09, 2023	BUY	$1.26 - $2.1 $359 - $598	285 Added 0.3%	95,606 $128,000
Q2 2023 Aug 11, 2023	SELL	$1.56 - $1.84 $23,451 - $27,660	-15,033 Reduced 13.62%	95,321 $171,000
Q1 2023 May 12, 2023	BUY	$1.6 - $2.48 $176,566 - $273,677	110,354 New	110,354 $183,000
Q3 2022 Nov 10, 2022	BUY	$0.29 - $4.04 $876 - $12,216	3,024 Added 116.49%	5,620 $13,000
Q2 2022 Aug 10, 2022	BUY	$3.24 - $5.85 $8,294 - $14,976	2,560 Added 7111.11%	2,596 $8,000
Q1 2022 May 16, 2022	SELL	$4.6 - $8.83 $2,175 - $4,176	-473 Reduced 92.93%	36 $0
Q4 2021 Feb 14, 2022	BUY	$7.75 - $10.05 $3,270 - $4,241	422 Added 485.06%	509 $4,000
Q3 2021 Nov 15, 2021	BUY	$7.78 - $10.0 $155 - $200	20 Added 29.85%	87 $1,000
Q2 2021 Aug 13, 2021	SELL	$9.22 - $14.48 $18,403 - $28,902	-1,996 Reduced 96.75%	67 $1,000
Q1 2021 May 12, 2021	BUY	$9.0 - $14.57 $18,567 - $30,057	2,063 New	2,063 $22,000

Others Institutions Holding NUVB

# of Institutions

152

Shares Held

123M

Call Options Held

9.7K

Put Options Held

6.5K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $508M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account